Company intelligence / Profile preview

Atlas Capital

Cambridge, Massachusetts, United Statesatlas-cap.com ↗

Ownership: Private
Development stage: Other

Overview

Atlas Venture does not conduct clinical trials itself but has launched over 70 biotech startups from its incubator. Its portfolio companies have developed at least 25 approved medicines and are running nearly 50 ongoing clinical trials as of late 2024. Recent successes include FDA approvals in pediatric low-grade glioma and major acquisitions by pharma partners for programs in obesity and radiopharmaceuticals.

Therapeutic areas: OncologyMetabolic DisordersEndocrinologyRare DiseasesImmunologyHematology
Modalities: Small moleculeMonoclonal antibodyGene therapyRNA therapyRadiopharmaceuticalsCell therapy
Industry: Investors

Partnerships

Co-investments with other VCs/fundsSyndicates backing newcos/startups

Beyond the preview

Go deeper on Atlas Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atlas Capital.

Explore the full profile